Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis (TRANSFORM-1)
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Of Navitoclax In Combination With Ruxolitinib Versus Ruxolitinib In Subjects With Myelofibrosis (TRANSFORM-1)
Sponsor: AbbVie
This PHASE3 trial investigates Myelofibrosis (MF) and is currently completed. AbbVie leads this study, which shows 31 recorded versions since 2020 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
31 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Dec 2025 [monthly]
Completed PHASE3
-
Mar 2025 — Sep 2025 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Sep 2024 — Mar 2025 [monthly]
Active Not Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
▶ Show 26 earlier versions
-
Apr 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
-
May 2023 — Apr 2024 [monthly]
Active Not Recruiting PHASE3
-
Feb 2023 — May 2023 [monthly]
Active Not Recruiting PHASE3
-
Dec 2022 — Feb 2023 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Nov 2022 — Dec 2022 [monthly]
Recruiting PHASE3
-
Sep 2022 — Nov 2022 [monthly]
Recruiting PHASE3
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE3
-
Jun 2022 — Jul 2022 [monthly]
Recruiting PHASE3
-
May 2022 — Jun 2022 [monthly]
Recruiting PHASE3
-
Apr 2022 — May 2022 [monthly]
Recruiting PHASE3
-
Feb 2022 — Apr 2022 [monthly]
Recruiting PHASE3
-
Jan 2022 — Feb 2022 [monthly]
Recruiting PHASE3
-
Dec 2021 — Jan 2022 [monthly]
Recruiting PHASE3
-
Nov 2021 — Dec 2021 [monthly]
Recruiting PHASE3
-
Oct 2021 — Nov 2021 [monthly]
Recruiting PHASE3
-
Sep 2021 — Oct 2021 [monthly]
Recruiting PHASE3
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE3
-
Apr 2021 — Jun 2021 [monthly]
Recruiting PHASE3
-
Mar 2021 — Apr 2021 [monthly]
Recruiting PHASE3
-
Feb 2021 — Mar 2021 [monthly]
Recruiting PHASE3
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE3
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE3
-
Nov 2020 — Dec 2020 [monthly]
Recruiting PHASE3
-
Oct 2020 — Nov 2020 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Sep 2020 — Oct 2020 [monthly]
Not Yet Recruiting PHASE3
-
Aug 2020 — Sep 2020 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- AbbVie
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aachen, Germany , Angers, France , Ankara, Turkey (Türkiye) , Ann Arbor, United States , Antwerp, Belgium , Athens, Greece , Atlanta, United States , Augusta, United States , Badalona, Spain , Barcelona, Spain and 156 more locations